Growth factors play a crucial role in regulating a broad variety of biological processes and have been regarded as powerful therapeutic agents in tissue engineering and regenerative medicine in the past decades. However, their application is limited by their short half‐lives and potential side effects in physiological environments. Hydrogels have been identified as having the promising potential to prolong the half‐lives of growth factors and mitigate their adverse effects by restricting them within the matrix to reduce their rapid proteolysis, burst release, and unwanted diffusion. This review discusses recent progress in the development of growth factor‐containing hydrogels for various biomedical applications, including wound healing, brain tissue repair, cartilage and bone regeneration, and spinal cord injury repair. In addition, the review introduces strategies for optimizing growth factor releases including affinity‐based delivery, carrier‐assisted delivery, stimuli‐responsive delivery, spatial structure‐based delivery, and cellular system‐based delivery. Finally, the review presents current limitations and future research directions for growth factor‐delivering hydrogels.This article is protected by copyright. All rights reserved

One hallmark of cancer cells is aberrant glucose metabolism. By desperately consuming glucose, cancer cells grow quickly and form a hypoxic core in the tumor, which severely limits the efficacy of oxygen‐dependent therapeutic strategies. Herein, a cell metabolism regulation strategy is adopted to reallocate cell respiration substrates for fueling the processes for cancer therapy by constructing a metabolism nanoregulator (denoted as ATO/GOx PLP). To be specific, a protoporphyrin IX (PpIX, the intermembrane‐translocatable accessory)‐doped liposome is employed for direct intracellular delivery of GOx and atovaquone (ATO, a mitochondrial complex III inhibitor). The PpIX‐doped liposome can efficiently avoid the cargo leakage in blood circulation. Benefiting from the translocation of PpIX from the liposome to the cancer cell membrane, ATO and GOx can be rapidly released upon encountering the plasma membrane and internalized by the cancer cell. By inhibiting mitochondrial oxidative phosphorylation and regulating mitochondrial function, ATO reduces both oxygen consumption and glucose metabolism, sparing more substrates for GOx to kill cancer cells. As a result, ATO/GOx PLP presents outstanding anticancer efficacies both in vitro and in vivo. In addition, the ATO/GOx PLP exhibits excellent biosafety, showing its clinical translation potential. Overall, this study provides a new approach to achieve efficacious metabolism regulation‐based cancer therapy.